About the Journal

The Journal of Immunotherapy and Precision Oncology (JIPO) is a publication of Global Academy of Health Sciences. This is a peer-reviewed online journal with quarterly print on-demand compilation of issues published. The journal allows free access (Open Access) to its contents and permits authors to self-archive a final accepted version of the articles on any OAI-compliant institutional/subject-based repository. 

Aim and Scope
JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology. The content will appeal to a broad readership of healthcare professionals and scientists, especially those with an interest in oncology and immunology. There will be innovative original articles including translational science and clinical medicine, review articles, editorials, controversy, and others. Manuscripts related to clinical and translational discoveries related with immunity and cancer and immunotherapy, such as new discoveries about immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, and more will be considered for publication. Subjects related to precision oncology including prognostic or predictive markers and innovative targeted therapy advances in diagnostic technology will also be considered. High quality evidence based guidelines of credible professional entities will also be considered for publication. Sub-topic based Supplements may be published. This allows the journal to highlight issues relevant to the Journal readers.

JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology.  The content will appeal to a broad readership of healthcare professionals and scientists, especially those with an interest in oncology and immunology. There will be innovative original articles including translational science and clinical medicine, review articles, editorials, controversy, and others.

Manuscripts related to clinical and translational discoveries related with immunity and cancer and immunotherapy, such as new discoveries about immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, and more will be considered for publication. Subjects related to precision oncology including prognostic or predictive markers and innovative targeted therapy advances in diagnostic technology will also be considered.

Sub-topic based Supplements may be published. This allows the journal to highlight issues relevant to the Journal readers. High quality evidence based guidelines of credible professional entities will be considered for publications.

Medknow Publications